Catalyst Event

Gilead Sciences Inc (GILD) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/2/2026, 12:00:00 AM

OtherSentiment: Positive

Announcement of statistically significant composite ALP normalization for Livdelzi (seladelpar) in the Phase 3 IDEAL trial for Primary Biliary Cholangitis (PBC) on June 2, 2026. Low impact estimated as the market had partially priced in success; expected.

Korean Translation

2026년 6월 2일, 원발성 담즙성 담관염(PBC)에 대한 3상 IDEAL 임상시험에서 리브델지(셀라델파)의 통계적으로 유의미한 복합 ALP 정상화 달성 발표가 예상됨. 시장의 선반영에 따른 낮은 영향이 예상됨.

Related Recent Events

View Full Timeline